Last updated: 2026-09-28 13:07:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
SCYNEXIS, Inc. (SCYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.77, with a market capitalization of $43.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.53 to $9.12. This page covers its latest market performance, valuation, price trends and company information.
$43.68M | |
$4.41 | |
$1,200.00 | |
$3.53 | |
$4.39 | |
4.81M | |
134.34K | |
-- | |
$9.12 | |
$3.53 | |
-- | |
-- |
SCYNEXIS, Inc. (SCYX) is trading at $4.77 in pre-market trading as of 2026-09-28 13:05:00, up 8.59% ($0.38) from the previous close of $4.39
Pre-market trading shows how investors are pricing SCYX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, SCYNEXIS, Inc. (SCYX) moved from $4.45 to $4.77, representing a gain of 7.17% ($0.32).
The stock traded between $4.11 and $6.30 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 69.85 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.2%
SCYX is currently trading at $4.77, placing it 22.2% of the way from its 52-week low of $3.53 to its 52-week high of $9.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SCYNEXIS, Inc. (SCYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.